Werewolf Therapeutics, Inc.
HOWLHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeWerewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other. With a market capitalization of $47.6M, it sits in micro-cap territory. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Market Cap
$47.6M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-1.66
EPS (TTM)
$-0.72
EPS (Fwd)
$-0.59
ROE
-119.9%
ROA
-27.4%
Cash
$22.0M
Total Debt
$0
Free CF
-$12.2M
52W Change
-42.0%
Annual Financials
Cash vs Debt
Where HOWL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HOWL finished 55.22% above its 150-day moving average ($0.67) and 57.58% above its 200-day moving average ($0.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HOWL overbought or oversold?
At the October 20, 2026 close, HOWL's RSI(14) was 71.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Werewolf Therapeutics, Inc. reports $22.0M in cash and $0 in total debt. Free cash flow is running at -$12.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -119.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $16.4M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Werewolf Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Werewolf Therapeutics, Inc.'s trajectory.